Hospital San Pedro De Alcantara — Clinical Trial Site

138 Registered trials

50 Currently recruiting

Organisation

Hospital San Pedro De Alcantara

Location

Caceres, Spain

Identifier

ORG-100032710

Address

Avenida De Pablo Naranjo Porras S/n, 10002, Spain

Departments

-
#1903:Cardiología
#3430: Cardiología
#4220:Servicio de Cardiología
#7015: Unidad de Ensayos Clinicos
#93158004: Oncología
#98358004: Oncology
1206:Oncología Médica
1316: Hematología
172401: Hematologia
3611; Oncología
4220: cardiologia
5500: Neumología
6001: Laboratorio de Inmunología y Genética Molecular
724001: Hematologia
Allergology
Cardiología
Cardiology
Cardiology Service
Clinical Haematology
Clinical Research
Departamento Oncología
ES045A: Hematología
ES30016: Hematologia
Haematology
Hematología
Hematology
Hematology and Hemotherapy Service
Hematology department
Hematology service
HOSPITAL SAN PEDRO DE ALCANTARA
Medica Oncology
Medical Oncology
Medical Oncology Service
Neomologia
Nephrology
neumologia
Neurology
None
Oncologia
Oncología Médica
Oncology
Oncology Service
Pneumology
Pulmonología
Respiratory medicine
Servicio de Hematología
Servicio de Oncología

Clinical trials at this site (138)

Search interface

A study to find how well budoprutug (TNT119) works and how safe it is in participants with immune thrombocytopenia Not authorised

2024-519745-30-00 Immune Thrombocytopenia (ITP) 9
"A Clinical Study to Evaluate the Effectiveness of Beltavac® with polymerized extract of grass pollen mixture in allergic rhinoconjunctivit… Not authorised

2025-520581-22-00 Allergic rhinoconjunctivitis caused due to exposure to 4
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending

2024-518026-32-00 Invasive Breast Cancer 5
A Study to Evaluate how Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) wh… Pending

2024-519709-37-00 Paroxysmal nocturnal hemoglobinuria (PNH) 5
A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologi… Pending

2024-520336-14-00 Post-chemotherapy neutropenia with high risk of develop 5
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Neoplasm Metastasis 5
A study to evaluate the safety and efficacy of oral decitabine plus ivosidenib in newly diagnosed adult patients with acute myeloid leukemia… Pending

2025-523238-17-00 Acute myeloid leukemia 4
Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS Pending

2025-523396-38-00 Relapse or refractory (r/r) acute myeloid leukaemia (AM 9
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia Pending

2025-524810-28-00 Acute Promyelocytic Leukemia 5
A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos… Recruiting

2024-511496-14-00 Newly Diagnosed Philadelphia Chromosome-Positive Acute 5 2026-05-14
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting

2024-512436-29-00 CARDIOVASCULAR DISEASES 11 2026-03-27
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me… Recruiting

2025-521919-39-00 Resected stage IIB, IIC, or III melanoma requiring adju 3 2026-02-10
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Acute myeloid leukemia 5 2025-05-05
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10… Recruiting

2024-512659-19-00 Advanced Melanoma 10 2025-03-31
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting

2024-513219-29-00 Renal Cell Carcinoma 5 2024-10-21
A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formu… Recruiting

2023-510017-26-00 Completely Resected Stage IIB, IIC, and III Melanoma 1 2024-10-02
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting

2025-522979-29-00 Acute myeloid leukemia 5 2026-04-30